Departamento de Oftalmología, Facultad de Medicina, Universidad de Murcia, Murcia, Spain.
Instituto Murciano de Investigación Biosanitaria Hospital Virgen de la Arrixaca (IMIB-Virgen de la Arrixaca), Murcia, Spain.
Acta Ophthalmol. 2022 Sep;100(6):e1313-e1331. doi: 10.1111/aos.15165. Epub 2022 May 5.
To study and compare effects of syngeneic bone marrow mononuclear stem cells (BM-MNCs) transplants on inherited retinal degeneration in two animal models with different etiologies: the RCS and the P23H-1 rats. To compare the safety and efficacy of two methods of intraocular delivery: subretinal and/or intravitreal.
A suspension of BM-MNCs was injected subretinally or intravitreally in the left eyes of P23H-1 and RCS rats at post-natal day (P) 21. At different survival intervals after the injection: 7, 15, 30 or 60 days, the retinas were cross-sectioned, and photoreceptor survival and glial cell responses were investigated using immunodetection of cones (anti-cone arrestin), synaptic connections (anti-bassoon), microglia (anti-Iba-1), astrocytes and Müller cells (anti-GFAP). Electroretinographic function was also assessed longitudinally.
Intravitreal injections (IVIs) or subretinal injections (SRIs) of BM-MNCs did not produce adverse effects. The transplanted cells survived for up to 15 days but did not penetrate the retina. Both IVIs and SRIs increased photoreceptor survival, decreased synaptic degeneration and glial fibrillary acidic protein (GFAP) expression in Müller cells but did not modify microglial cell activation and migration or the electroretinographic responses.
Intravitreal and subretinal syngeneic BM-MNCs transplantation decreases photoreceptor degeneration and shows anti-gliotic effects on Müller cells but does not ameliorate retinal function. Moreover, syngeneic BM-MNCs transplants are more effective than the xenotransplants of these cells. BM-MNC transplantation has potential therapeutic effects that merit further investigation.
研究并比较同种骨髓单核干细胞(BM-MNCs)移植对两种病因不同的动物模型(RCS 和 P23H-1 大鼠)遗传性视网膜变性的影响。比较两种眼内给药方法的安全性和有效性:视网膜下和/或玻璃体内。
在 P23H-1 和 RCS 大鼠出生后第 21 天(P)将 BM-MNCs 悬浮液经视网膜下或玻璃体内注射到左眼。在注射后不同的存活间隔(7、15、30 或 60 天),将视网膜切片,使用抗锥体(抗锥体 arrestin)、突触连接(抗 bassoon)、小胶质细胞(抗 Iba-1)、星形胶质细胞和 Müller 细胞(抗 GFAP)免疫检测来研究光感受器的存活和神经胶质细胞的反应。还进行了长期的视网膜电图功能评估。
玻璃体内注射(IVIs)或视网膜下注射(SRIs)BM-MNCs 不会产生不良反应。移植细胞可存活长达 15 天,但不会穿透视网膜。IVIs 和 SRIs 均可增加光感受器的存活,减少突触变性和 Müller 细胞中的神经胶质纤维酸性蛋白(GFAP)表达,但不会改变小胶质细胞的激活和迁移或视网膜电图反应。
玻璃体内和视网膜下同种异体 BM-MNCs 移植可减少光感受器变性,并对 Müller 细胞具有抗神经胶质作用,但不能改善视网膜功能。此外,同种异体 BM-MNCs 移植比这些细胞的异种移植更有效。BM-MNC 移植具有潜在的治疗效果,值得进一步研究。